Abstract: A strip of fasteners for loading into a fastening tool, the strip of fasteners including a plurality of elongated fasteners arranged in a parallel side-by-side relationship, each of the elongated fasteners having a head for driving the fastener into a substrate, the strip being arranged such that the heads of the fasteners are located along one side of the strip, and wherein at least one fastener has a head with an indicator for indicating to an operator upon driving of said fastener that the strip is due for replacement.

Abstract: The specification describes a method for the production of a hydrochlorination catalyst, comprising the steps of: i) preparing an impregnation solution by combining a source of gold and a ligand in a solvent, wherein the solvent comprises an organic solvent; ii) impregnating a support with the impregnation solution from step (i); and iii) drying the product of step (ii) to obtain the catalyst. Also described are hydrochlorination catalysts comprising a complex of gold and a ligand of Formula (I) supported on a support. These catalysts are particularly suitable for the conversion of acetylene to vinyl chloride monomer.

Abstract: The present invention relates to improvements in known gold containing catalysts. In particular, the present invention relates to improving the stability and/or inhibition of deactivation of gold containing catalysts via the addition of an inorganic oxide, hydroxide, oxo-salt or oxo-acid. There is also disclosed a method for preparing said catalyst most suitably via an impregnation method. Such catalysts are useful in the production of vinyl chloride monomer.

Abstract: Disclosed are devices, methods and/or systems for a partial glenoid implant for use during glenoid arthroplasty, including related surgical methods and instruments.

Abstract: The present invention relates to improvements in known gold containing catalysts. In particular, the present invention relates to improving the stability and/or inhibition of deactivation of gold containing catalysts via the addition of an inorganic oxide, hydroxide, oxo-salt or oxo-acid. There is also disclosed a method for preparing said catalyst most suitably via an impregnation method. Such catalysts are useful in the production of vinyl chloride monomer.

Abstract: Disclosed are devices, methods and/or systems for a partial glenoid implant for use during glenoid arthroplasty, including related surgical methods and instruments.

Abstract: Components may modify an audio input signal to produce an output audio signal. The audio input signal is firstly rectified and sent to the peak detector as an input control signal. The peak detector produces a peak value which correlates to the level of the input control signal. The control signal is then sent from the peak detector to a dynamic curve module, which has two user selectable inputs: a threshold level and a knee/dynamic angle. The control signal is then sent from the dynamic curve module to the signal dynamics processor. This processor is then configurable to modify the control signal by applying an attack and release phase waveform to elements of the signal which exceed the threshold set by the user. The user will have selected the release time and the release phase shape prior to use of the processor. The release shape is selected by the user.

Abstract: Components may modify an audio input signal to produce an output audio signal. The audio input signal is firstly rectified and sent to the peak detector as an input control signal. The peak detector produces a peak value which correlates to the level of the input control signal. The control signal is then sent from the peak detector to a dynamic curve module, which has two user selectable inputs: a threshold level and a knee/dynamic angle. The control signal is then sent from the dynamic curve module to the signal dynamics processor. This processor is then configurable to modify the control signal by applying an attack and release phase waveform to elements of the signal which exceed the threshold set by the user. The user will have selected the release time and the release phase shape prior to use of the processor. The release shape is selected by the user.

Abstract: The present invention provides an implantable bioreactor comprising cells enclosed within an enclosure, said cells being capable of producing paracrine factors, wherein the enclosure is collapsible or expandable or both or neither, wherein the enclosure is semipermeable such that it provides containment of the cells preventing the egress of the cells while further providing a barrier that shields the cells from immunological attack, and wherein the enclosure is permeable to the entire secretome of the cell including exosomes, nucleic acids and proteins. The implantable bioreactor can have various configurations and can house internally a cell culture matrix than can include hydrogels, microbeads, and nanofiber matrices along with other active agents.

Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.

Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.

Abstract: A method of making a supported catalytic species comprising an alloy of at least two metals, comprises the steps of: (i) combining a particulate support material, a solution of a first metal compound, a solution of a second metal compound, and a solution of an alkaline precipitating agent to form a slurry mixture; (ii) agitating the resultant mixture; and (iii) contacting the solids with a reducing agent, wherein the first metal in the first metal compound and the second metal in the second metal compound is each independently selected from the group consisting of gold, palladium, platinum, rhodium, iridium, silver, osmium and ruthenium; and wherein the first metal is not the same as the second metal.

Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.

Abstract: A catalyst including gold, or a compound thereof, and sulphur, a compound of sulphur, trichloroisocyanuric acid or a metal dichloroisocyanurate on a support, together with a process for manufacturing the catalyst and its use in a chemical process are described.

Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.

Abstract: The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.

Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.

Abstract: A method of making a supported catalytic species comprising an alloy of at least two metals, comprises the steps of: (i) combining a particulate support material, a solution of a first metal compound, a solution of a second metal compound, and a solution of an alkaline precipitating agent to form a slurry mixture; (ii) agitating the resultant mixture; and (iii) contacting the solids with a reducing agent, wherein the first metal in the first metal compound and the second metal in the second metal compound is each independently selected from the group consisting of gold, palladium, platinum, rhodium, iridium, silver, osmium and ruthenium; and wherein the first metal is not the same as the second metal.

Abstract: An implantable bioreactor containing a barrier which is designed to allow the release of cell-derived biomolecules, but restricts the entry of immunologic and other cells, or the egress of the cells contained within the bioreactor. Two broad classes of implantable bioreactors are envisioned, encompassing devices for both systemic delivery of the bio-products and local delivery at the target tissue. Bioreactors of both classes can be implanted via surgery, through percutaneous techniques, or other techniques which effect implantation.